Brainstorm Cell Therapeutics (BCLI) Reports Q2 Loss of $0.16/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
BrainStorm Announces Financial Results for the Second Quarter of 2018 and Provides a Corporate Update
July 23, 2018 8:00 AM EDTNEW YORK and PETACH TIKVAH, Israel, July 23, 2018 /PRNewswire/ --Â BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today financial results for the second quarter and six months ended June 30, 2018.
"We are pleased with our accomplishments in the second quarter of 2018. Â We continue to execute on the ongoing Phase... More
